LianBio plans to wind down operations, sell assets, delist from Nasdaq, and reduce workforce by 50%, with a special cash dividend of $4.80 per share.

LianBio, a troubled biotechnology company, announced its plan to wind down its operations, including selling its pipeline assets, delisting its American Depositary Shares from Nasdaq, and reducing its workforce by more than 50%. The company's board declared a special cash dividend of $4.80 per ordinary share, totaling approximately $528 million. LianBio anticipates a substantial portion of its wind-down activities to be completed by the end of 2024.

February 13, 2024
5 Articles